Articles On Pharmaust (ASX:PAA)

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders approved the moniker change at Wednesday’s AGM. The new name “combines our focus on neuro-degenerative diseases with the...

  ASX closes  higher with consumer and utilities leading the charge Wall Street rally boosts sentiment as Nvidia jumps 4pc China’s CSI 300 index falls 5pc amid doubts over stimulus plans   The ASX closed 0.13% higher on Wednesday, thanks...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Stockhead’s Sarah Hughan sits down with PharmAust (ASX:PAA) managing director Dr Michael Thurn to get the short end of the long story on the company’s latest news. The biotech has requested Orphan Medicinal Product Designation in the EU for...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Dr Michael Thurn, Managing Director at PharmAust (ASX:PAA). PharmAust recently submitt...

Birth rates decline as people choose careers and pets Global pet industry is benefitting from this, to grow significantly by 2030 Ethical investing could thrive in sustainable pet product demand   The conversation around motherhood is evo...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

  ASX slips after hitting new high ahead of Fed decision Iron ore prices expected to drop below US$80 by 2025 Harvey Norman faces class action lawsuit over warranties   The ASX was a bit of a mixed bag today, hitting a new high before pu...

PharmAust submits a request for orphan medicinal product designation to the EMA for monepantel to treat amyotrophic lateral sclerosis The designation will provide PharmAust with significant regulatory support and commercial benefits Pharm...

PharmAust (ASX: PAA) has requested the European Medicines Agency (EMA) grant orphan medicinal product designation (OMPD) for monepantel (MPL), its lead candidate in the treatment of amyotrophic lateral sclerosis (ALS) and motor neurone dise...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Morgans has a Speculative Buy rating for PharmAust with a target price of 42c, up from 18c Monepantel, originally for veterinary use, has shown potential in slowing ALS progression The upcoming Phase 2/3 trial is a critical catalyst for Ph...

ASX 200 down on Tuesday; energy and iron ore stocks rise BHP’s profit up 2pc, but dividend cut. Lovisa drops 12pc; Zip Co loses over 10pc despite strong revenue   The ASX traded cautiously following a mixed session on Wall Street. At the...

Actinogen doubled on positive Phase 2a results for Xanamem Xanamem’s durability leads to a Phase 2b Alzheimer’s trial PharmAust’s monepantel showed promising ALS results   Actinogen doubles on promising Phase 2a trial data Actinogen Medic...

PharmAust (ASX: PAA) has received promising interim results from a major study into monepantel (MPL), its lead amyotrophic lateral sclerosis (ALS) / motor neurone disease (MND) treatment candidate. The clinical-stage biotechnology company r...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The three months to end June marked a transformative quarter in PharmAust’s (ASX: PAA) focus on monepantel (MPL) for the treatment of neurodegenerative diseases. The company achieved numerous milestones in the development of MPL for motor n...

PharmAust (ASX: PAA) has raised $7.8 million in a share purchase plan (SPP) to accelerate development of its lead candidate monepantel as a viable treatment for motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS). Shareholder...

Special Report: PharmAust has achieved a major milestone after its lead investigational drug, monepantel, was selected for inclusion in the prestigious HEALEY ALS Platform Trial in the US under a Clinical Research Support Agreement with Mas...

PharmAust’s (ASX: PAA) lead amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) treatment candidate monepantel (MPL) has been selected for inclusion in the prestigious HEALEY ALS Phase 2/3 platform trial. The HEALEY trial is bei...

ASX health stocks fall 0.19% in past five days as broader markets lift 0.79% Morgans says capital raises remain a theme for 2024 among healthcare stocks Pharmaceutical distributor EBOS increases stake in MedAdvisor to 9.8% Healthcare and...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has been granted small and medium-sized enterprise (SME) status by the European Medicines Agency (EMA). PharmAust is now eligible to receive regulatory fee incentives and additional...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Fraser Palamara dives into the mega $10 million raising PharmAust (ASX:PAA) announced today via an institutional placement. Funds fr...

PharmAust raises $10 million via institutional placement to progress pivotal trial Share price has rallied in 2024 as data shows lead drug monepantel significantly improves MND/ALS survival rates PharmAust makes key appointments to positio...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has received strong market support for plans to progress its monepantel (MPL) neurodegenerative disease candidate. The company has received binding commitments to raise $10 million v...

ASX closes lower, but Energy sector blinks green Uranium mining stocks surged on Peter Dutton’s nuclear plans VanEck to launch Australia’s first Bitcoin ETF tomorrow    Local shares closed Wednesday -0.1% lower as gains in Energy were of...

The success of PharmAust’s (ASX: PAA) Phase 1 MEND study into the treatment of motor neurone disease/amyotrophic lateral sclerosis (MND/ALS) is being showcased at a major global gathering of medical professionals in Stockholm, Sweden. Texas...

Aussie stocks start the week flat; energy and tech sectors lead declines Investor caution prevails ahead of RBA rates decision Chinese Premier Li Qiang meets PM in Canberra today   Aussie stocks had a lacklustre start to the week on Monda...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has appointed US-based Dr Katie MacFarlane as a non-executive director to the board. Dr MacFarlane has over 30 years’ experience in the development and commercialisation of pharmaceu...

ASX health stocks fall in past five days in line with broader markets on mixed economic signals The ACCC raises concerns about proposed merger of Sigma Healthcare and unlisted Chemist Warehouse Radiopharmaceuticals-focused Telix Pharmaceut...

Aussie shares rise in arvo trade Resources sectors weigh, Real Estate adds 2pc GDP lowest in 40 years ex. COVID   The local bourse has come home with a sail wet on Wednesday with the ordinariness of our economy bringing market joy as it d...

PharmAust reports promising updates on MPL’s efficacy in treating MND/ALS New data suggests MPL significantly reduces the risk of death by 91% in MND/ALS patients The next step is the Open-Label Extension (OLE) study, where enrolment has j...

PharmAust Limited (ASX: PAA) shares are catching the eye with a strong gain on Wednesday. At the time of writing, the ASX healthcare stock is up almost 20% to 24.5 cents. Why is this ASX healthcare stock rocketing? Investors have been biddi...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has received positive survival benefit assessments for its monepantel (MPL) neurodegenerative disease treatment. A new study undertaken by specialists Berry Consultants indicates tha...

05 Jun 2024 - A snapshot of the stocks on the move, featuring Calmer Co International (ASX:CCO), PharmAust (ASX:PAA & PAAOA) and Magnum Mining & Exploration (ASX:MGU).

  The Calmer Co. International (ASX:CCO), a health and wellness company focussing on natural products that promote calmness, support relaxation and improve sleep. Informs shareholders that May sales have materially increased with ecommerce...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

The ASX200 is trading up around 0.55% With strong performances from major medical companies, the healthcare sector is leading gains, up 1.2%, Discretionary follows, up nearly a per cent. IT is the only sector to fall into the red, dow...

PharmAust reappoints Dr Michael Thurn as managing director and CEO to lead its push in human neurodegenerative diseases Company has also appointed neuroscientist Dr Nicky Wallis as its chief scientific officer Phase 2/3 clinical trial of M...

FDA approves AVITA’s RECELL GO System Wound care medical company, AVITA Medical ASX:AVH), surged +13% this morning after receiving an FDA approval for its latest product, the RECELL GO System. The RECELL GO system basically harvests a small...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has strengthened its leadership team as it progresses a number of key treatments for neurodegenerative diseases. In addition to reappointing Dr Michael Thurn as chief executive offic...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

PharmAust receives US FDA orphan drug designation for monepantel (MPL) to treat motor neurone disease Application based on preclinical mechanistic data showing that MPL can induce autophagy in diseased cells PharmAust preparing for upcomin...

PharmAust (ASX: PAA) has achieved a major breakthrough in plans to commercialise its monepantel (MPL) treatment for motor neurone disease with the receipt of an orphan drug designation (ODD) from the US Food and Drug Administration (FDA). T...

  To register for today's webinar click here. PharmAust (ASX:PAA & PAAOA) announced it has received Orphan Drug Designation (ODD) from the United States Food and Drug Administration for monepantel and its treatment of Motor Neurone Dise...

17 May 2024 - A snapshot of the stocks on the move, featuring PharmAust (ASX:PAA), Impact Minerals (ASX:IPT) and Peregrine Gold (ASX:PGD).